Dr. Robert Huizinga reports

KANE BIOTECH ANNOUNCES PUBLICATION OF REVYVE WOUND GEL ARTICLE IN THE INTERNATIONAL WOUND JOURNAL

Kane Biotech Inc . has published an article on its revyve anti-microbial wound gel in the International Wound Journal. The article, "Wound Healing Property of a Novel Thermo-Reversible Wound Gel With Lasting Antimicrobial and Antibiofilm Activity," is first written by Dr. Jeyachchandran Visvalingam, internal R&D (research and development) leader, and includes authors from the Miller School of Medicine, Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami.

Key messages of the article as it relates to Kane's revyve wound gel include:

• The thermo-reversible gel shifts from a low viscosity liquid to a form-fitting gel at body temperature and then reliquefies when cooled for easy, atraumatic removal;
• revyve demonstrated efficacy against a broad range of wound-related pathogens, including Staphylococcus aureus and Pseudomonas aeruginosa, with a 99.99-per-cent to 99.9999-per-cent reduction in bacterial counts within 30 minutes.
• There was sustained in vitro activity for up to seven days, potentially reducing the number of dressing changes.
• The safety and non-cytotoxicity of the gel were validated through biocompatibility testing and a porcine wound-healing study.

U.S. FDA 510(k)-cleared and Health Canada-approved revyve anti-microbial wound gel

The International Wound Journal is a peer-reviewed scientific journal focused on research in wound care and wound healing. It publishes original studies, clinical research and reviews that advance knowledge in wound prevention, treatment and management.

"Having our research published in the International Wound Journal underscores the scientific rigour behind revyve technology and provides independent, peer-reviewed validation of the gel's safety, in vitro performance and clinical potential," said Dr. Robert Huizinga, interim chief executive officer. "Recognition in such a respected global wound-care publication strengthens our credibility with clinicians, regulators and commercial partners and reinforces our commitment to advancing evidence-based solutions that improve patient outcomes."

About Kane Biotech Inc.

Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve anti-microbial wound gel, revyve anti-microbial wound gel spray and revyve anti-microbial skin and wound cleanser are all U.S. FDA 510(k) cleared. revyve anti-microbial wound gel and revyve anti-microbial wound gel spray are also Health Canada approved.

We seek Safe Harbor.